Technology | Radiation Therapy | October 20, 2017

Xstrahl Photoelectric Therapy System Receives FDA 510(k) Clearance

System provides high-dose treatment for various types of skin cancer

Xstrahl Photoelectric Therapy System Receives FDA 510(k) Clearance

October 20, 2017 — Xstrahl announced that its Photoelectric Therapy System has received U.S. Food and Drug Administration (FDA) 510(k) clearance for treatment of skin cancer. The Photoelectric Therapy System is a compact and ergonomic superficial X-ray therapy system operating in the 10kV to 80kV range intended for superficial radiotherapy and surface electronic brachytherapy treatment of primary malignant epithelial neoplasms of the skin and keloids.

Utilizing trusted and clinically proven low energy photons in a dedicated treatment system, the Photoelectric Therapy System provides a pain-free, non-surgical alternative for the treatment of non-melanoma skin cancer and superficial lesions, especially those found in sensitive areas of the head and neck.

Using an ideal depth dose profile for the treatment of superficial skin lesions, the high dose output enables treatment times to be kept to a minimum in the same manner as electronic brachytherapy systems while treating a wider range of skin conditions. The low half-value layer (HVL) of the system allows for higher doses without compromising on depth of delivery.

Typical applications include treatment for:

  • Basal cell carcinoma;
  • Squamous cell carcinoma;
  • Metatypic carcinoma;
  • Cutaneous appendage carcinoma;
  • Karposi's sarcoma;
  • Merkel cell carcinoma;
  • Lentigo maligna;
  • Lentigo maligna melanoma;
  • Cutaneous lymphomas (B and T cell); and
  • Keloids.

The system is freestanding, self-contained, unobtrusive, compact and lightweight, which helps to ensure a reassuring and stress-free patient experience in any clinical facility. The system is mounted on lockable castors, allowing free movement and operation in any clinical space. It features ergonomically designed controls ensuring smooth adjustment and safe, simple patient set-up. The system requires connection to the clinical facilities electrical supply and room interlocks, but generates X-rays using a 24V power supply.

Photoelectric therapy devices require minimal shielding as compared to higher energy X-ray therapy systems.

For more information: www.xstrahl.com

Related Content

Important milestone demonstrates the unrivalled experience, technological innovation and global market leadership of IBA and its clinical partners
News | Proton Therapy | September 25, 2020
September 25, 2020 — IBA (Ion Beam Applications SA) announced that more than 100,000 patients have now been treated w
Final rule includes mandatory participation for nearly 1,000 practices and does not allow sufficient time for transition

Getty Images

News | Radiation Oncology | September 21, 2020
September 21, 2020 — In response to the September 18 ...
According to a new report published by P&S Intelligence, the global radiotherapy market is expected to expand from $7.2M in 2019 to $17M by 2030.

Image courtesy of Accuray

Feature | Radiation Therapy | September 21, 2020 | By Melinda Taschetta-Millane
According to a...
Breast cancer patients whose disease has spread to their brains fare better if their metastases are picked up before they begin to cause symptoms, according to a study presented at the 12th European Breast Cancer Conference.

Getty Images

News | Breast Imaging | September 21, 2020
September 21, 2020 — Breast cancer patients whose disease has spread to their brains fare better if their metastases
Data from latest research presented at the ESMO Virtual Congress 2020 suggests COVID-19 pandemic halts cancer care and damages oncologists' wellbeing

Getty Images

News | Coronavirus (COVID-19) | September 17, 2020
September 17, 2020 — Delays and cancellation of cancer treatments and other safety measures undertaken to minimize th
Varian Drives Next Evolution of Proton Treatment Planning with Eclipse v16.1
News | Treatment Planning | September 15, 2020
September 15, 2020 — Varian announced it has received FDA 510(k) clearance for its Eclipse v16.1 treatment planning s
the Contrast Media Injectors Market is estimated to be USD 1.3 billion in 2020 and  projected to reach $1.9B by 2025, at a CAGR of 7.4% between 2020 and 2025

Getty Images

News | Contrast Media Injectors | September 02, 2020
September 2, 2020 — According to the new market research report "...
Single-dose radiotherapy replaces need for extra hospital visits, with benefits for patient safety and well-being

Getty Images

News | Women's Health | August 20, 2020
August 20, 2020— For most women with early breast cancer